Veri Medtech (VRHI) Files Registration Statement for Proposed Initial Public Offering
Rhea-AI Summary
Veri Medtech (OTC: VRHI) filed a Form S-1 registration statement with the U.S. SEC on November 17, 2025 for a proposed initial public offering of Class A common stock.
The company has not disclosed the number of shares or price range; the offering is subject to market conditions and may not be completed. The securities cannot be sold until the registration statement is declared effective, and any offering will be made only by prospectus in compliance with securities laws. The release includes standard forward-looking statements and a disclaimer that company materials are informational and not investment advice.
Positive
- Filed Form S-1 for proposed IPO on Nov 17, 2025
- Initiates formal SEC process toward public market access
Negative
- No share count or price range disclosed
- Offering completion is not assured and subject to market conditions
News Market Reaction
On the day this news was published, VRHI gained 2.19%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- OTC Markets -- Veri Medtech Holdings, Inc. (Stock Ticker Symbol: “VRHI”) ("Veri Medtech"), healthcare technology platform, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its Class A common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The proposed offering will be made only by means of a prospectus. A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.
Company Information: The information provided on the company’s website, press releases, in related materials, and in any documents or communications distributed by Veri Medtech Holdings, Inc. (the “Company”) is for informational purposes only. Company information does not constitute an offer or solicitation to sell shares or securities in the Company or any related or associated entity. Any such offer or solicitation will be made solely through a Company offering memorandum or similar formal investment documentation, in strict accordance with the terms of all applicable securities laws and regulations.
No information, statements, or analyses presented on this site, on the Company’s website, or in any Company media, or in Company materials, are intended to form the basis of any investment decision, nor do they constitute investment advice, recommendations, or counsel. This material does not constitute or form part of — and should not be construed as — any offer for sale or subscription, or any invitation to offer to buy or subscribe for any securities, nor should it or any part of it form the basis of, or be relied upon in connection with, any contract or commitment of any kind. The Company expressly disclaims any and all liability for any direct or consequential loss or damage arising directly or indirectly from: (i) reliance on any information provided here or in related materials; (ii) any error, omission, or inaccuracy in such information; or (iii) any action taken or decision made based on such information.
Forward-Looking Statements: Cautionary Note Regarding Forward-Looking Statements: This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Veri Medtech (OTC: "VRHI") and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements.
About Veri Medtech (OTC Markets: VRHI): Veri Medtech is a publicly-traded healthcare technology company that offers alternative medicine, personalized diagnostics, and wellness medication on demand. The company leverages telehealth infrastructure, diagnostic intelligence, and scalable digital systems to meet the growing demand for accessible, stigma-free healthcare. Strategically positioned for growth, Veri MedTech actively explores acquisitions that complement its core capabilities and enhance patient engagement across emerging sectors of alternative medicine, longevity, and wellness science. With a strong integration and operational efficiency track record, the company drives accelerated revenue through the continuous generation of high-value patient databases and recurring service models. With a commitment to innovation and patient-centric care, Veri MedTech continues to expand its services and reach, aiming to make personalized healthcare more accessible and effective for all. For more information, please visit: www.VeriMedTech.com
About Veriheal: Veriheal, a wholly-owned subsidiary of publicly-traded Veri Medtech Holdings - OTC Markets (“VRHI”), is a healthcare technology company on a mission to help people gain access to alternative medicine treatments. For more information, please visit: www.Veriheal.com
About DosePop: DosePop, a wholly-owned subsidiary of publicly-traded Veri Medtech Holdings - OTC Markets (“VRHI”), provides a one-stop healthcare technology platform for mental and physical health, all designed to empower you to take charge of your well-being. From weight loss solutions to anti-aging, our treatments are backed by science and administered by licensed professionals. For more information, please visit: www.DosePop.com
About Global Telemedicine: The global telemedicine market size was valued at USD 114.98 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of
For Press inquiries: verimedtechpr@gmail.com
FAQ
What did Veri Medtech (VRHI) announce on November 17, 2025?
Has Veri Medtech (VRHI) disclosed the IPO price range or share count?
When can Veri Medtech (VRHI) begin selling shares in the IPO?
Does the Veri Medtech (VRHI) filing guarantee the IPO will happen?
Where will Veri Medtech (VRHI) provide official offering details for investors?
